Study at University of Miami identifies next-gen BTK degrader compound for resistant CLL patients, published in Science.

Researchers at the Sylvester Comprehensive Cancer Center have discovered a next-generation BTK degrader, NX-2127, which could help overcome treatment resistance in chronic lymphocytic leukemia (CLL) and related blood cancers. The compound effectively destroyed its cellular targets in both petri dishes and patient cells, shrinking tumors in 11 of 14 CLL patients participating in the study. This could offer a therapeutic option for patients whose tumors become drug-resistant or are unresponsive to frontline treatment.

February 01, 2024
5 Articles